Net Loss Narrows to $4.02 Million in Q2 2023 for ACASTI PHARMA INC

ACASTI PHARMA INC.(ACST), a pharmaceutical compa ny specializing in cardiovascular treatments, has released its condensed consolidated interim financial statements for the second quarter of 2023. The company reported a narrowed net loss of $4.02 million for the quarter, accompanied by steady revenue growth, which reached $15.01 million. The financial report provides insights into the company's current financial position and its ongoing efforts in research and development.

Assets Reflect Strategic Allocation

ACASTI PHARMA INC. showcased its strategic allocation of assets in its Condensed Consolidated Interim Balance Sheet for June 30, 2023. The company's total assets amounted to $73.03 million, a decrease from the previous quarter's $79.12 million. The decline was primarily driven by a decrease in cash and cash equivalents, as well as short-term investments. Current assets totaled $23.61 million, including $21.63 million in cash and cash equivalents, $15,000 in short-term investments, and $837,000 in receivables.

Liabilities and Equity Dynamics